Prev Next

BP-C1 Oncology

BP-C1 is a unique product that clinically has proven to have both strong palliation properties as well as tumor control properties. more

BP-C2 Radiation Defence

BP-C2 incorporates immunomodulating and chelating ligand and a molybdenum, needed for detoxification. more

BP-C1 Oncology

BP-C1 is a unique product that clinically has proven to have both strong palliation properties as well as tumor control properties. more

Scientific Publications

This section contains a select list of scientific publications on drug candidates in Meabco’s pipeline.


An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

Steen Lindkær-Jensen, Claus L. Jensen, Naiel Azzam, Rinat Bar-Shalom, Basem Fares, Nina Habib, Stig Larsen and Fuad Fares

Published Date: February 28, 2016

Journal of Hematology & Thromboembolic Diseases


BP-C2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment:  A Case of Advanced Inoperable Pancreatic Cancer.

Ibrahim T, Larsen S, Lindkær Jensen NH, Lindkær-Jensen S. 

J Clin Case Rep 2015; 5: 514. doi:10.4172/2165-7920.1000514

Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.

Navolotskii DV, Ivanenko NB, Solovyev ND, Fedoros EI, Panchenko AV.

Drug Test Anal. 2015 Sep;7(9):737-44. doi: 10.1002/dta.1824.

An Innovative Complex of Benzene-Poly-Carboxylic Acid and Molybdenum, for Prevention and Treatment of Radiation Dermatitis

Fuad Fares, Basem Fares, Naiel Azzam, Munir Nashashibi, Alex Nevelsky, Stig Larsen and Steen Lindkær-Jensen


Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance.

Lindkær-Jensen S, Larsen S, Habib-Lindkær-Jensen N, Fagertun HE

Published Date: 13 March 2015


BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkær-Jensen S

Published Date November 2014 Volume 2014:6 Pages 179—189


Benzene-Poly-Carboxylic Acid Complex, a Novel Anti-Cancer Agent Induces Apoptosis in Human Breast Cancer Cells

Fuad Fares, Naiel Azzam, Fares, Stig Larsen, Steen Lindkaer-Jensen

Published: February 11, 2014, DOI: 10.1371/journal.pone.0085156 

Quality of life, efficacy and tolerability of long term treatment with BP-C1, in patients with stage IV breast cancer

Stig Larsen, S. Lindkaer-Jensen

EACR23-EJC, 2014, European Journal of Cancer

Page 286, s201,829


Between- and within-patient n-level response surface pathway design in dose-finding studies

Sagita Dewi, Veronica Kristiansen, Steen Lindkaer-Jensen, Stig Larsen

Published Date July 2014 Volume 2014:6 Pages 63—74 


Benzene-Poly-Carboxylic Acids Complex with Cis-Diammineplatinum (II) Dichloride in the Treatment of Stage IV Breast Cancer Patients

Sagita Dewi, Stig Larsen, Vichien Srimuninnimit, Yen-Shen Lu, Tjakra Manuaba, Steen Lindkaer-Jensen

The Open Breast Cancer Journal, 2013, 5, 7-15


Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours

Veronica. Kristiansen, S. Dewi, T. E. Horsberg,  T. J. Jonasdottir, L. Moe, B. Berlinger, S. Lindkær-Jensen and S. Larsen
Veterinary and Comparative Oncology

MEABCO A/S  |  Richard Mortensens Vej 61  |  DK-2300 Copenhagen  |  Telephone: +45 32 46 03 70  | e-mail:
Websitet anvender cookies til at huske dine indstillinger, statistik og at målrette annoncer. Når du besøger vores hjemmeside, accepterer du automatisk vores brug af Cookies.